Mineralys has been on the radar for some biotech investors. Read more about MLYS' hypertension treatment, upcoming trial ...

Heart failure arises when the heart cannot pump blood efficiently, leading to symptoms such as shortness of breath and ...

High blood pressure, or hypertension, is a serious health issue that can lead to heart disease, strokes, and other problems.

Our data is showing a move in the right direction.” The largest increase in 90-day prescriptions is a 20% jump for aldosterone antagonists, a treatment for high blood pressure and heart failure.

Increase in endogenous cortisol production achieved in all patients in higher dose cohorts of BBP-631, a result seen for the ...

In a report released on September 6, Mohit Bansal from Wells Fargo maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – ...

The magnitude of the effect was dependent on the class of blood pressure lowering medication, with greater effect observed in those on β-blockers, Renin-angiotensin-aldosterone system (RAAS) ...

Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar AwardAllschwil, Switzerland – September 5, 2024Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, ...

(CNN) — A medication that is currently used for chronic kidney disease in patients with type 2 diabetes has been found to reduce the risk of worsening heart failure and cardiovascular death in certain ...

RADNOR, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and ...